Biotech and Pharmaceuticals Pharmaceuticals

  • Pharma deal flurry 'start of things to come': Pro

    James West, healthcare analyst at Results Healthcare, says the pharmaceutical sector is "dynamic" and the flurry of deals is likely to continue.

  • How Ackman built Allergan stake

    CNBC's Eamon Javers reports on Bill Ackman's stake in Allergan. Javers says this is a classic case of insider trading that is not against the rules.

  • Ackman: Partnership with Valeant is not front running

    William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • Valeant CEO: Deal will get done despite 'poison pill'

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • Merger mania sweeps Wall Street

    CNBC's Patti Domm discusses the amount of merger activity happening this week with a big three-way deal in the drug industry, and the $46 billion bid by Valeant and activist Bill Ackman for Allergan.

  • Show me accretive pharma: O'Leary

    "Shark Tank" investor Kevin O'Leary discusses recent mergers between pharmaceutical companies.

  • Biotech earnings: All eyes on Gilead

    CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.

  • Next big pharma target

    CNBC's Meg Tirrell; Herb Greenberg, CNBC contributor, and Arindam Nag, Mergermarket, discuss potential takeover targets in the pharmaceutical space.

  • How to play big pharma

    Barbara Ryan, CNBC contributor, shares an inside look at what's happening among the drug giants as billion dollar deals are announced and big player reshape the industry.

  • Pharma's big deal frenzy

    These companies have a lot of money and are signaling what they plan to do going forward, reports CNBC's Meg Tirrell on the mega deals in big pharma.

  • Allergan, Valeant perfect match: CEO

    CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.

  • Bill Ackman

    Valeant Pharmaceuticals and Bill Ackman are proposing a cash-and-stock deal for Allergan that could be worth about $45 billion.

  • Novartis strikes multiple deals

    The "Squawk on the Street" news team discuss all the M&A activity going on in pharma after Novartis is reported to be purchasing GlaxoSmithKline's oncology products unit for $14.5 billion. Separately Novartis is selling its animal health division to Eli Lilly for $5.4 billion in cash.

  • The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.

  • Eli Lilly acquires Novartis' animal health unit

    Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.

  • GlaxoSmithKline CEO: Widest portfolio of vaccines in world

    GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.